Source comparison
Does MK-677 Support Deep Sleep Optimization? Comparison Table
MK-677 (25mg evening) Ghrelin receptor agonism → pulsatile GH release +50% Stage 3/4 duration (JCEM 1997 trial) Improved REM latency, reduced fragmentation None documented Restores natural sleep architecture without suppression. Ideal for aging-related SWS dec
This comparison does not assign a generated winner or score.
- MK-677 (25mg evening)
- Ghrelin receptor agonism → pulsatile GH release
- +50% Stage 3/4 duration (JCEM 1997 trial)
- Improved REM latency, reduced fragmentation
- None documented
- Restores natural sleep architecture without suppression. Ideal for aging-related SWS decline
- Zolpidem (10mg)
- GABA-A receptor agonist → CNS depression
- Reduced Stage 3/4 quality despite subjective 'depth'
- Suppressed REM duration by 15–20%
- High. Tolerance develops in 2–4 weeks
- Fast sleep onset but poor restorative quality. Not suitable for long-term use
- Melatonin (3–5mg)
- MT1/MT2 receptor agonism → circadian alignment
- Minimal direct effect on SWS depth
- Slight improvement in REM continuity
- None
- Regulates sleep timing, not architecture. Useful for jet lag, limited for SWS optimization
- Exogenous GH injection
- Direct GH receptor activation (non-pulsatile)
- No SWS improvement. Flat delivery negates rhythm benefit
- No significant change
- None (but expensive, invasive)
- Does not replicate endogenous pulsatility. Misses the circadian synchronization MK-677 provides
- Cognitive Behavioral Therapy for Insomnia (CBT-I)
- Sleep hygiene, stimulus control, cognitive restructuring
- Improves SWS consolidation through behavioral optimization
- Stabilizes REM cycles indirectly
- First-line non-pharmacological intervention. Pairs well with MK-677 for compounded effect
- MK-677 stands out because it addresses the cause of age-related sleep degradation. Declining ghrelin sensitivity and flattened GH pulsatility. Rather than masking symptoms with sedation.